Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objectives Respiratory syncytial virus (RSV) causes respiratory infection across the world, with infants and the elderly at particular risk of developing severe disease and death. The replication-defective chimpanzee adenovirus (PanAd3-RSV) and modified vaccinia virus Ankara (MVA-RSV) vaccines were shown to be safe and immunogenic in young healthy adults. Here we report an extension to this first-in-man vaccine trial to include healthy older adults aged 60–75 years. Methods We evaluated the safety and immunogenicity of a single dose of MVA-RSV given by intra-muscular (IM) injection (n = 6), two doses of IM PanAd3-RSV given 4-weeks apart (n = 6), IM PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), intra-nasal (IN) spray of PanAd3-RSV prime and IM MVA-RSV boost 8-weeks later (n = 6), or no vaccine (n = 6). Safety measures included all adverse events within one week of vaccination and blood monitoring. Immunogenicity measures included serum antibody responses (RSV- and PanAd3-neutralising antibody titres measured by plaque-reduction neutralisation and SEAP assays, respectively), peripheral B-cell immune responses (frequencies of F-specific IgG and IgA antibody secreting cells and memory B-cells by ex vivo and cultured dual-colour ELISpot assays respectively), and peripheral RSV-specific T-cell immune responses (frequencies of IFNγ-producing T-cells by ex vivo ELISpot and CD4+/CD8+/Tfh-like cell frequencies by ICS/FACS assay). Results The vaccines were safe and well tolerated. Compared with each individual baseline immunity the mean fold-changes in serum RSV-neutralising antibody, appearance and magnitude of F-specific IgG and IgA ASCs and expansion of CD4+/CD8+ IFNγ-producing T-cells in peripheral circulation were comparable to the results seen from younger healthy adults who received the same vaccine combination and dose. There were little/no IgA memory B-cell responses in younger and older adults. Expansion of IFNγ-producing T-cells was most marked in older adults following IM prime, with balanced CD4+ and CD8+ T cell responses. The RSV-specific immune responses to vaccination did not appear to be attenuated in the presence of PanAd3 (vector) neutralising antibody. Conclusions PanAd3-RSV and MVA-RSV was safe and immunogenic in older adults and the parallel induction of RSV-specific humoral and cellular immunity merits further assessment in providing protection from severe disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Groothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292102 · Cited by 744
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555 · cited 1×
“[54] [55] [56] [57] In conclusion, we report the first clinical study for replicationdefective viral-vectored RSV vaccines for towards the elderly population in need of protection from severe RSV disease.”
Magro, M., Mas, V., Chappell, K., Vázquez, M., Cano, O., Luque, D., Terrón, M. C., Melero, J. A., & Palomo, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115941109 · Cited by 271 · cited 1×
“[54] [55] [56] [57] In conclusion, we report the first clinical study for replicationdefective viral-vectored RSV vaccines for towards the elderly population in need of protection from severe RSV disease.”
Duerr, A., Huang, Y., Buchbinder, S., Coombs, R. W., Sanchez, J., del Rio, C., Casapia, M., Santiago, S., Gilbert, P., Corey, L., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis342 · Cited by 210
McElhaney, J. E., Beran, J., Devaster, J.-M., Esen, M., Launay, O., Leroux-Roels, G., Ruiz-Palacios, G. M., van Essen, G. A., Caplanusi, A., Claeys, C., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70046-x · Cited by 164 · cited 2×
“[1] [2] [3] [4] The elderly differ from younger adults in having a greater risk of disease progressing to the lower-respiratory tract causing respiratory failure (8-13%) and death (2-5%).”
Cited by
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationFrederiksen, L. S. F., Zhang, Y., Foged, C., & Thakur, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01817 · Cited by 287
Alsaleh, G., Panse, I., Swadling, L., Zhang, H., Richter, F. C., Meyer, A., Lord, J., Barnes, E., Klenerman, P., Green, C., et al. (2020) · eLife · doi:10.7554/elife.57950 · Cited by 120
“Calculation of triplicate well variance was performed as described previously (Green et al., 2019).”
Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey, I., & Saelens, X. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1675520 · Cited by 32
“adenovirus vaccine being given either intramuscularly or intranasally) were evaluated in healthy younger and older adults and all regimens were found to be safe and well tolerated [85,87].”
BackgroundResultInnate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys
Collignon, C., Bol, V., Chalon, A., Surendran, N., Morel, S., van den Berg, R. A., Capone, S., Bechtold, V., & Temmerman, S. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579872 · Cited by 29
Self-citation
Metadata
- Authors
- Green, C. A., Sande, C. J., Scarselli, E., Capone, S., Vitelli, A., Nicosia, A., Silva-Reyes, L., Thompson, A. J., de Lara, C. M., Taylor, K. S., Haworth, K., Hutchings, C. L., Cargill, T., Angus, B., Klenerman, P., & Pollard, A. J.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 78
- Issue
- 5
- Pages
- 382-392
- ISSN
- 0163-4453 (ISSN-L)
- OpenAlex
- W2911905205
- Cited by
- 45
- References
- 8
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. https://app.cochat.ai/papers/10.1016/j.jinf.2019.02.003
- The paper
- Green, C. A., Sande, C. J., Scarselli, E., Capone, S., Vitelli, A., Nicosia, A., Silva-Reyes, L., Thompson, A. J., de Lara, C. M., Taylor, K. S., Haworth, K., Hutchings, C. L., Cargill, T., Angus, B., Klenerman, P., & Pollard, A. J. (2019). Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. Journal of Infection. https://doi.org/10.1016/j.jinf.2019.02.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.